Alectinib CAS 1256580-46-7: Advancing Targeted Cancer Therapy with Precision
Discover the quality and value of Alectinib for advanced cancer treatment.
Get a Quote & SampleProduct Core Value
Alectinib
Alectinib is a potent and selective tyrosine kinase inhibitor used in the treatment of Anaplastic Lymphoma Kinase (ALK)-positive non-small-cell lung cancer (NSCLC). It targets specific genetic mutations that drive cancer growth, offering a more precise and effective treatment approach.
- This pharmaceutical intermediate is crucial for ALK-positive NSCLC treatment, offering significant patient benefit.
- Explore the benefits of buying Alectinib CAS 1256580-46-7 from reliable suppliers for your research and development needs.
- As a leading ALK inhibitor, Alectinib plays a vital role in targeted cancer therapy, improving patient outcomes.
- This high purity Alectinib supplier ensures consistent quality for pharmaceutical chemicals used in cancer therapy.
Advantages Offered
Targeted Efficacy
Alectinib's mechanism of action as an ALK inhibitor provides highly specific therapeutic effects, minimizing damage to healthy cells and improving the efficacy of cancer treatment.
Improved Patient Outcomes
Clinical trials show that Alectinib's use in treating ALK-positive NSCLC leads to better progression-free survival rates and enhanced overall patient well-being.
Versatile Application
Beyond first-line treatment, Alectinib is also approved for adjuvant treatment of early-stage lung cancer, showcasing its versatility in managing the disease.
Key Applications
Oncology
A critical component in the fight against cancer, particularly non-small-cell lung cancer driven by ALK mutations.
Lung Cancer Treatment
Specifically targets ALK-positive advanced and early-stage lung cancer, offering a more personalized treatment strategy.
Targeted Cancer Therapy
Represents a significant advancement in precision medicine, focusing on molecular targets for more effective treatment.
Pharmaceutical Research
Serves as a key pharmaceutical intermediate and reference standard in research and development for new cancer therapies.